Hepatocellular carcinoma
Conditions
Interventions
Control group:Placebo
Sponsors
Changhai Hospital of Traditional Chinese Medicine,Navy Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged older than 18 years; 2. Histologically diagnosed HCC, OR clinically diagnosed HCC; 3. Documented progression with or intolerance to target therapy for advanced HCC and no indication of transarterial chemoembolization and radiotherapy; 4. Stage C and D according to the BCLC staging classification; 5. More than 1 month from the last TACE or 2 months from the last radiotherapy. 6. The estimated survival time is more than 2 months; 7. Willing to participate in clinical trials and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; 2. Local treatment including radiotherapy (except palliative radiotherapy), percutaneous ethanol injection, radiofrequency ablation, transarterial embolization, or cryotherapy administered within 4 weeks prior to enrollment; 3. Had a solid organ transplant; 4. Presence of brain or leptomeningeal metastases; 5. Has had esophageal or gastric variceal bleeding within the last 6 months; 6. the researchers consider those who were not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactXiaofeng Zhai
Changhai Hospital of Traditional Chinese Medicine,Navy Military Medical University
Outcome results
None listed